MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 9, 2012, Pages 1337-1339

  Grimaldi, Luigi M E ^a   Prosperini, Luca ^b   Vitello, Gaetano ^a   Borriello, Giovanna ^b   Fubelli, Federica ^b   Pozzilli, Carlo ^b  

^a UO Neurology   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

magnetic resonance imaging; multiple sclerosis; natalizumab

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; RADIOACTIVITY; RISK ASSESSMENT; UPPER RESPIRATORY TRACT INFECTION;

EID: 84866048499     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512439438     Document Type: Article

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
3. Outteryck O, Ongagna JC, Zéphir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010 ; 257: 207-211
4. Mancardi GL, Tedeschi G, Amato MP, et al. Three years of experience: the Italian registry and safety data update. Neurol Sci. 2011 ; 31: 295-297
5. Stüve O, Bennett JL.. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007 ; 13: 79-95
6. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 ; 348: 15-23
7. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol. 2010 ; 68: 395-399
8. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
9. Ghezzi A, Grimaldi LM, Marrosu MG, et al. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society. Neurol Sci. 2011 ; 32: 351-358
10. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Post-withdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008 ; 70: 1150-1151